Fighting the Wrong Enemy: Antibacteriophage Immunity in Phage Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Characterization, antibacterial, and cytotoxic activities of silver nanoparticles using the whole biofilm layer as a macromolecule in biosynthesis.Scientific reports · 2024
   Article
2. Do Anti-Phage Antibodies Persist after Phage Therapy? A Preliminary Report.Antibiotics (Basel, Switzerland) · 2022
   Article

Corrections and comments

• Comment on
  Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia.2023

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as